维普中文期刊产品整合服务
232篇 您的检索式:作者名="Partridge R"
    题名 作者 年代 出处 被引量
1Delamination resistant laminates by Z-fiber pinning Ⅰ: Manufacture and fracture performance 显示文摘Partridge I K Carrie D D R 2005Composites Part A2005,36,1:1
2显示文摘 Leonowicz M E Partridge R D 1998Microporous Mesoporous Mater1998,109,117:1
3Detection of rare disseminated tumor cells identifies head and neck cancer patients at risk of treatment failure显示文摘Partridge M Brakenhoff R Phillips E 2003Clin Cancer Res2003,9,14:1
4Definition of heattil site of class 1 integrons显示文摘Partridge S R Recchia G D S caramuzzi C 2000Microbiol2000,146,1:1
5Transforming growth factor - betal regulation of ATF - 3 and identification of ATF - 3 target genes in breast cancer cells 显示文摘Kwok S Rittling S R Partridge N C 2009J Cell B iochem2009,108,2:1
6Amino-acid imbalance explains extension of lifespan by dietary restriction in Drosophila 显示文摘Grandison R C Piper M D W Partridge L 2009Nature2009,462,7276:1
7Lower Pliocene hominid remains from Sterkfontein 显示文摘Partridge T C Granger D E Caffee M W Clarke R J 2003Science2003,300,5619:1
8Oxygen uptake and carbohydrate metabolism by in vitro derived bovine embryos显示文摘THOMPSON J G PARTRIDGE R J HOUGHTON F D 1996J Reprod Fertil1996,106,2:1
9Horizontal gene transfer in a polyclonal outbreak of carbapenem-resistant Acinetobacter baumannii 显示文摘Valenzuela J K Thomas L Partridge S R 2007J Clinic Microbiol2007,45,2:1
10Postischemic hyperglycemia is not protective to the neonatal rat brain显示文摘Sheldon R A Partridge J C Ferriero D M 1992Pediatr Res1992,32,:1
11Delamination resistant lami-nates by Z fiber pinning: Part I manufacture and fracture per- formance 显示文摘Partridge I K Carti6 D D R 2005Composites Part A: Applied Science and Man ufacturing2005,36,1:1
12Pairing and Phase Separation in a Polarized Fermi Gas显示文摘PARTRIDGE G B LI WENHUI KAMAR R I 2006Science2006,311,:1
13Parameters for the Lyman Kutcher Burman(LKB)model of normal tissue complication probability(NTCP)for specific rectal complications observed in clinical practise显示文摘Gulliford S L Partridge M Sydes M R 2012Radiotherapy and Oncology2012,102,3:1
14Delamination of Z- pinned carbon fibre reinforced laminates 显示文摘Carti6 D D R Troulis M Partridge I K 2006Composites Sci- ence and Technology2006,66,6:1
153D reinforcement of stiffener-to skin T-joints by z pinning and tufting 显示文摘Carrie D D R Dell'Anno G Poulin E Partridge I K 2006Engineering Fracture Mechanics2006,73,:1
16Do emergency physi-cians use serum D-dimer effectively to determine the need for CT when evaluating patients for pulmonary embolism?Review of 5 344 consecutive patients显示文摘Corwin MT Donoboo JH Partridge R 0,,11:1
17hori- zontal gene transfer in a polyclonal outbreak of carbapenem - re-sistant acinetobacter baumannii 显示文摘VALENZUELA J K THOMAS L PARTRIDGE S R 2007J Clin Microbiol2007,45,2:1
18早期乳腺癌最佳辅助化疗方案与人类表皮生长因子受体2阳性乳腺癌辅助靶向治疗选择:依据 ASCO 对 CCO临床实践指南的改编显示文摘目的研究加拿大安大略癌症治疗中心(CCO)关于早期乳腺癌最佳辅助化疗方案,包括人类表皮生长因子受体2(HER2)阳性乳腺癌辅助靶向治疗方案,并对其进行改编。方法按照美国临床肿瘤协会(ASCO)对其他组织临床实践指南改编的策略和程序,对CCO临床实践指南的严谨性与内容适用性进行回顾。结果基于对CCO临床实践指南内容的回顾,ASCO小组认为,CCO临床实践指南在整体上清晰全面,以最确切的科学证据为基础,为患者提供可接受的治疗选项。推荐关于辅助化疗方案的决定,应考虑到基线复发风险、毒性、利益可能性和宿主因素(如合并症)。对于高风险HER2阴性的身体状况良好的人群,蒽环类和紫杉烷治疗方案是标准治疗方案。4个周期的多西他赛和环磷酰胺治疗方案是可接受的非蒽环类治疗方案。对于高风险HER2阳性患者,推荐蒽环类与紫杉烷序贯疗法联合曲妥单抗或多西他赛、卡铂、曲妥单抗进行6个周期的治疗。对于低风险、非淋巴结转移、HER2阳性人群,推荐每周一次的紫杉醇和曲妥单抗连续进行12个周期的替代治疗。曲妥单抗应持续使用1年。不应采用铂复合盐对三阴性人群进行常规的辅助管理,除非出现有效的生存数据加以支持。Neelima Denduluri Mark R Somerfield Andrea Eisen Jamie N Holloway Arti Hurria Tari A King Gary H Lyman Ann H Partridge Melinda L Telli Maureen E Trudeau Antonio C Wolff 本刊编辑部 2016中国全科医学2016,19,18:1
19Mechanical properties balance in novel Z pinned sandwich panels: out-of-plane properties显示文摘MARASCO A I CARTIE DENIS D R PARTRIDGE I K 2006Composites Part A Applied Science and Manufacturing2006,37,:1
20Twelve-ring pockets on the external surface of MCM-22 crystals显示文摘LAWTON S L LEONOWICZ M E PARTRIDGE R D 1998Microporous and Mesoporous Materials1998,23,:1
返回顶部 每页显示:
共12页 首页 上一页 第1页 下一页 末页 /12 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费